NRXP · NRX Pharmaceuticals, Inc. · Share Buybacks
Substantial doubt about the company's ability to continue as a going concern.
“the Company has concluded that substantial doubt exists about the Company's ability to continue as a going concern for a period of at least twelve months from the date of issuance of these consolidated financial statements.”View the 10-Q filed Aug 14, 2026
Share-repurchase activity from the company's own XBRL filings — cash spent buying back common stock per fiscal year and per recent quarter, share counts where the company tagged them, and the buyback program's authorization — paired with the company's at-the-market (ATM) equity offering programs, the dilution side of the same picture. Repurchase amounts come exclusively from tagged SEC data; program figures with no tagged equivalent (untagged authorizations and all ATM figures) are read from the filing's own text and shown only after verification.
Equity Offering (ATM) Programs
| Program Established | Last Amended | Capacity | Remaining | Runs Through | Source |
|---|---|---|---|---|---|
| 2023-08-14 | 2025-04-04 | $20,000,000 | — | — | 8-K , filed 2026-02-17 |
Cash spent on buybacks by quarter
Cash deployed each quarter. Δ marks quarters derived from the company's cumulative year-to-date disclosures.
Repurchase History
| Quarter Ended | Cash Spent | Source |
|---|---|---|
| 2020-09-30 | $299,253 Δ | 10-Q, filed 2020-11-16 |
| 2020-06-30 | $0 Δ | 10-Q, filed 2020-08-14 |
| 2020-03-31 | $25,997,965 | 10-Q, filed 2020-05-15 |
| 2019-09-30 | $8,891,378 Δ | 10-Q, filed 2020-11-16 |
| 2019-06-30 | $22,099,233 Δ | 10-Q, filed 2020-08-14 |
| 2019-03-31 | $0 | 10-Q, filed 2020-05-15 |
| 2018-09-30 | $0 Δ | 10-Q, filed 2019-11-14 |